Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of ASP7517 in Relapsed/Refractory AML and Higher-Risk MDS
jRCT1080224851Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Gene Therapies
01
Overview
Phase 2, open-label, single-arm trial of ASP7517 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Astellas Pharma. Primary endpoint: Primary safety and tolerability. Started Sep 2019; status: completed.
02
Drugs
ASP7517
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT1080224851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224851.